VALEANT PHARMACEUTICALS INTL
COM · CUSIP 91911K102
3
institutional holders
+0 vs Q1 2020
1.4m
shares reported held*
$25.1mreported value*
0 new
1 added
0 reduced
0 sold out
net bought ≈ $914.1k (+50.0k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $18.29.
Trends to Q2 2020
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2019 | 2 |
| Q1 2020 | 3 |
| Q2 2020 | 3 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2020 | 1 | 0 |
| Q2 2020 | 1 | 0 |
Biggest buyers
| Bruce & Co., Inc. | Added | +50.0k |
Biggest sellers
| None |
Holders, Q2 2020
| Manager | Shares | Change |
|---|---|---|
| Bruce & Co., Inc. 5.41% of their portfolio | 1.4m $24.9m | Added +50.0k |
| LeJeune Puetz Investment Counsel LLC 0.12% of their portfolio | 12.8k $233.0k | Unchanged |
| IFP Advisors, Inc 0.00% of their portfolio | 0 $0 | Unchanged |